AdvanCell Reports Positive Phase 1 Cancer Trial Results
New data shows promising efficacy for the radiopharmaceutical therapy ADVC001 in treating metastatic prostate cancer.
Updated on Oct. 23, 2026 in Cancer
Live Poll
Would you consider participating in an experimental clinical trial for a new cancer therapy?
AdvanCell presented updated Phase 1 clinical trial results for its targeted therapy, ADVC001, at the ESMO 2026 Congress. The study highlights significant response rates among patients with metastatic prostate cancer.
Why it matters
The trial aims to address unmet medical needs for patients with metastatic prostate cancer by testing the efficacy of a Lead-212 alpha-emitting payload. These findings support further clinical development and the optimization of dosage strategies.
In a study of 22 patients, the therapy achieved an 80 percent PSA50 response rate at recommended dose levels and a 100 percent objective response rate in target lesions. The median radiographic progression-free survival reached 11.2 months.
The players
AdvanCell
AdvanCell is a biopharmaceutical company with headquarters in Boston and Brisbane, Australia, focused on developing targeted alpha therapy.
ESMO 2026 Congress
The ESMO 2026 Congress is a major international oncology event held in Madrid, Spain, where researchers present clinical trial breakthroughs.
The details
ADVC001 is a PSMA-targeted radiopharmaceutical therapy that utilizes a Lead-212 alpha-emitting payload with a half-life of 10.6 hours. The study utilized escalating doses ranging from 60 to 200 MBq administered at intervals of 1 to 6 weeks to determine safety and tolerability.
Timeline
Initial TheraPb study results were reported in 2025.
The data cut-off for the trial results was October 5, 2026.
Updated results were presented at the ESMO Congress in October 2026.
The Big Picture
The TheraPb Phase 1 trial establishes a critical benchmark for evaluating the effectiveness of alpha-emitting payloads in prostate cancer treatment. This report updates the findings previously established by the clinical research program.
These results suggest that targeted alpha therapies could provide new treatment options for patients with metastatic prostate cancer. Patients should consult their oncologists regarding the current availability of clinical trials for this therapy.
The takeaway
The successful application of alpha-emitting payloads represents a significant step forward in targeted cancer treatments. Patients are encouraged to discuss the potential of radiopharmaceutical therapy with their medical teams as clinical evidence continues to evolve.
What happens next
Phase 2 enrollment is ongoing to further evaluate 160 MBq and 200 MBq doses, incorporating a dosing strategy of up to 12 cycles.
Further reading
For more information on current developments in oncology, visit the Cancer section.
Live Poll
Would you consider participating in an experimental clinical trial for a new cancer therapy?
